Previous Bladder Cancer History in Patients with High-Risk, Non–muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to assess the correlation of previous bladder cancer history with the recurrence and progression of patients with high-risk non–muscle-invasive bladder cancer treated with adjuvant Bacillus Calmette–Guérin (BCG) and to evaluate their natural history. Materials and Methods Patients were divided into two groups based on the existence of previous bladder cancer (primary, non-primary). A logistic regression analysis was used to identify the possible differences in the probabilities of recurrence and progression with respect to tumor history, while potential differences due to gender, tumor size (> 3 cm, < 3 cm), stage (pTa, T1), concomitant carcinoma in situ (pTis) and number of tumors (single, multiple) were also assessed. Univariate and multivariate models were employed. In addition, Kaplan-Meier survival analysis was used to compare recurrence- and progression-free survival between the groups. Results A total of 192 patients were included (144 with primary and 48 with non-primary tumors). The rates of recurrence and progression for patients with primary tumors were 27.8% and 12.5%, respectively. The corresponding percentages for patients with non-primary tumors were 77.1% and 33.3%, respectively. The latter group of patients displayed significantly higher probabilities of recurrence (p=0.000; 95% confidence interval [CI], 4.067 to 18.804) and progression (p=0.002; 95% CI, 1.609 to 7.614) in a univariate logistic regression analysis. Previous bladder cancer history remained significant in the multivariate model accounting for history, age, gender, tumor size, number of tumors, stage and concomitant pTis (p=0.000; 95% CI, 4.367 to 21.924 and p=0.002; 95% CI, 1.611 to 8.182 for recurrence and progression respectively). Kaplan-Meier curves revealed that the non-primary group hadreduced progression- and recurrence-free survival. Conclusion Previous non–muscle-invasive bladder cancer history correlates significantly with recurrence and progression in patients with high-risk nonmuscle-invasive disease treated with adjuvant BCG.
Abstract
Purpose The purpose of this study was to assess the correlation of previous bladder cancer history with the recurrence and progression of patients with high-risk non–muscle-invasive bladder cancer treated with adjuvant Bacillus Calmette–Guérin (BCG) and to evaluate their natural history. Materials and Methods Patients were divided into two groups based on the existence of previous bladder cancer (primary, non-primary). A logistic regression analysis was used to identify the possible differences in the probabilities of recurrence and progression with respect to tumor history, while potential differences due to gender, tumor size (> 3 cm, < 3 cm), stage (pTa, T1), concomitant carcinoma in situ (pTis) and number of tumors (single, multiple) were also assessed. Univariate and multivariate models were employed. In addition, Kaplan-Meier survival analysis was used to compare recurrence- and progression-free survival between the groups. Results A total of 192 patients were included (144 with primary and 48 with non-primary tumors). The rates of recurrence and progression for patients with primary tumors were 27.8% and 12.5%, respectively. The corresponding percentages for patients with non-primary tumors were 77.1% and 33.3%, respectively. The latter group of patients displayed significantly higher probabilities of recurrence (p=0.000; 95% confidence interval [CI], 4.067 to 18.804) and progression (p=0.002; 95% CI, 1.609 to 7.614) in a univariate logistic regression analysis. Previous bladder cancer history remained significant in the multivariate model accounting for history, age, gender, tumor size, number of tumors, stage and concomitant pTis (p=0.000; 95% CI, 4.367 to 21.924 and p=0.002; 95% CI, 1.611 to 8.182 for recurrence and progression respectively). Kaplan-Meier curves revealed that the non-primary group hadreduced progression- and recurrence-free survival. Conclusion Previous non–muscle-invasive bladder cancer history correlates significantly with recurrence and progression in patients with high-risk nonmuscle-invasive disease treated with adjuvant BCG.
참고문헌 (17)
- Sylvester RJ, "Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder", Eur Urol, 57, pp.766~773 (2010)
- Sylvester RJ, "Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer : a meta-analysis of the published results of randomized clinical trials", J Urol, 168, pp.1964~1970 (2002)
- Lee CT, "Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion", Urology, 69, pp.1068~1072 (2007)
- Herr HW, "Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?", J Urol, 166, pp.1296~1299 (2001)
- Saint F, "Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin(BCG)immunotherapy exist? : analysis of a quarter century of literature", Eur Urol, 43, pp.351~360 (2003)
- Sylvester RJ, "Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables : a combined analysis of 2596 patients from seven EORTC trials", Eur Urol, 49, pp.466~477 (2006)
- Fernandez-Gomez J, "Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin : multivariate analysis of data from four randomized CUETO trials", Eur Urol, 53, pp.992~1001 (2008)
- Zachos I, "Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscleinvasive bladder cancer patients treated with adjuvant BCG", Tumour Biol, 35, pp.4185~4189 (2014)
- Lamm DL, "Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder : a randomized Southwest Oncology Group Study", J Urol, 163, pp.1124~1129 (2000)
- Takashi M, "Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin(Tokyo 172 strain)therapy : significance of concomitant carcinoma in situ", Int Urol Nephrol, 33, pp.41~47 (2002)
- Losa A, "Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder : long-term results", J Urol, 163, pp.68~71 (2000)
- Alkhateeb SS, "Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors", J Urol, 184, pp.81~86 (2010)
- Thomas F, "Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer", Eur Urol, 63, pp.145~154 (2013)
- Martinez-Pineiro JA, "Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer", BJU Int, 89, pp.671~680 (2002)
- Hurle R, "Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy : a 7-year follow-up", Urology, 54, pp.258~263 (1999)
- Schrier BP, "Prognosis of muscle-invasive bladder cancer : difference between primary and progressive tumours and implications for therapy", Eur Urol, 45, pp.292~296 (2004)
- El-Abbady AA, "Repeated transurethral resection of recurrent superficial bladder tumors: does it affect the spread and stage of the tumor?", Scand J Urol Nephrol, 36, pp.60~64 (2002)